The Febrile Neutropenia Market is on the cusp of significant evolution, with projections suggesting a robust expansion in market share over the next decade. According to available data, the market size is forecasted to reach 20.15 USD by 2035, driven by a compound annual growth rate of 4.99%. The increasing prevalence of febrile neutropenia among cancer patients, particularly those undergoing...